Movatterモバイル変換

[0]ホーム
URL:

EP4512407A3 - Oligonucleotides for modulating rtel1 expression - Google Patents

Oligonucleotides for modulating rtel1 expression

Info

Publication number
EP4512407A3
EP4512407A3EP24208954.8AEP24208954AEP4512407A3EP 4512407 A3EP4512407 A3EP 4512407A3EP 24208954 AEP24208954 AEP 24208954AEP 4512407 A3EP4512407 A3EP 4512407A3
Authority
EP
European Patent Office
Prior art keywords
rtel1
oligonucleotides
modulating
relates
hbv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24208954.8A
Other languages
German (de)
French (fr)
Other versions
EP4512407A2 (en
Inventor
Marco BERRERA
Josephine FELBER
Jean-Christophe HOFLACK
Susanne KAMMLER
Tony KAM-THONG
Brian Leonard
Lykke PEDERSEN
Philipp TROPBERGER
Miriam Triyatni
Daniel Jeremy TURLEY
Angelina WALLIER
Jitao David ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AGfiledCriticalF Hoffmann La Roche AG
Publication of EP4512407A2publicationCriticalpatent/EP4512407A2/en
Publication of EP4512407A3publicationCriticalpatent/EP4512407A3/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
EP24208954.8A2018-07-132019-07-11Oligonucleotides for modulating rtel1 expressionPendingEP4512407A3 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
EP181834772018-07-13
EP19739971.0AEP3821013B1 (en)2018-07-132019-07-11Oligonucleotides for modulating rtel1 expression
PCT/EP2019/068639WO2020011902A1 (en)2018-07-132019-07-11Oligonucleotides for modulating rtel1 expression

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
EP19739971.0ADivisionEP3821013B1 (en)2018-07-132019-07-11Oligonucleotides for modulating rtel1 expression

Publications (2)

Publication NumberPublication Date
EP4512407A2 EP4512407A2 (en)2025-02-26
EP4512407A3true EP4512407A3 (en)2025-09-24

Family

ID=62951968

Family Applications (2)

Application NumberTitlePriority DateFiling Date
EP24208954.8APendingEP4512407A3 (en)2018-07-132019-07-11Oligonucleotides for modulating rtel1 expression
EP19739971.0AActiveEP3821013B1 (en)2018-07-132019-07-11Oligonucleotides for modulating rtel1 expression

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
EP19739971.0AActiveEP3821013B1 (en)2018-07-132019-07-11Oligonucleotides for modulating rtel1 expression

Country Status (16)

CountryLink
US (1)US20210147850A1 (en)
EP (2)EP4512407A3 (en)
JP (2)JP7616987B2 (en)
KR (1)KR20210033004A (en)
CN (1)CN112534055A (en)
AU (1)AU2019300324A1 (en)
BR (1)BR112021000538A2 (en)
CA (1)CA3106288A1 (en)
CL (1)CL2021000018A1 (en)
CR (1)CR20210015A (en)
IL (1)IL279929A (en)
MX (1)MX2021000404A (en)
PE (1)PE20211306A1 (en)
SG (1)SG11202100348SA (en)
TW (1)TWI791868B (en)
WO (1)WO2020011902A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
TW202246500A (en)2021-02-022022-12-01瑞士商赫孚孟拉羅股份公司Enhanced oligonucleotides for inhibiting rtel1 expression
WO2023111210A1 (en)2021-12-172023-06-22F. Hoffmann-La Roche AgCombination of oligonucleotides for modulating rtel1 and fubp1
CN116064471B (en)*2022-09-302024-05-31中国海洋大学 Lipase OUC-Lipase17 and its application in the preparation of free astaxanthin

Citations (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040162249A1 (en)*2002-08-292004-08-19Chun LiangTreatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotides inhibition of human replication-initiation proteins
WO2009058014A2 (en)*2007-11-022009-05-07Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En PatientenzorgPolypeptides involved in neuronal regeneration-associated gene expression
WO2013173635A1 (en)*2012-05-162013-11-21Rana Therapeutics, Inc.Compositions and methods for modulating gene expression
WO2014187856A1 (en)*2013-05-212014-11-27Deutsches KrebsforschungszentrumNucleoli disorganisation by knocking down specific alu-repeat containing rna sequences
WO2014205105A1 (en)*2013-06-192014-12-24The Regents Of The University Of CaliforniaBiomarkers of response to inhibition of poly-adp ribose polymerase (parp) in cancer
WO2016011080A2 (en)*2014-07-142016-01-21The Regents Of The University Of CaliforniaCrispr/cas transcriptional modulation
WO2016073990A2 (en)*2014-11-072016-05-12Editas Medicine, Inc.Methods for improving crispr/cas-mediated genome-editing

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP2823959B2 (en)1991-10-241998-11-11アイシス・ファーマシューティカルス・インコーポレーテッド Derivatized oligonucleotides with improved uptake and other properties
JP3756313B2 (en)1997-03-072006-03-15武 今西 Novel bicyclonucleosides and oligonucleotide analogues
ATE293123T1 (en)1997-09-122005-04-15Exiqon As BI- AND TRI-CYCLIC - NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGS
CA2361318C (en)1999-02-122008-11-25Sankyo Company, LimitedNovel nucleosides and oligonucleotide analogues
US7053207B2 (en)1999-05-042006-05-30Exiqon A/SL-ribo-LNA analogues
US6617442B1 (en)1999-09-302003-09-09Isis Pharmaceuticals, Inc.Human Rnase H1 and oligonucleotide compositions thereof
AU2003281969B2 (en)2002-11-182011-01-27Roche Innovation Center Copenhagen A/SAmino-LNA, thio-LNA and alpha-L-oxy-LN
DK1606406T4 (en)2003-03-212013-12-16Santaris Pharma As Short Interfering RNA (siRNA) Analogues
US8350021B2 (en)2003-06-122013-01-08Alnylam Pharmaceuticals, Inc.Conserved HBV and HCV sequences useful for gene silencing
US20090221679A1 (en)2005-08-102009-09-03Amy EspesethNovel HIV Targets
WO2007031091A2 (en)2005-09-152007-03-22Santaris Pharma A/SRna antagonist compounds for the modulation of p21 ras expression
ES2516815T3 (en)2006-01-272014-10-31Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids modified at position 6
CA2638837A1 (en)2006-01-272007-08-02Santaris Pharma A/SLna modified phosphorothiolated oligonucleotides
EP2002004B1 (en)2006-03-232015-10-14Roche Innovation Center Copenhagen A/SSmall internally segmented interfering rna
CN101490074B (en)2006-05-112013-06-26Isis制药公司 5'-Modified Bicyclic Nucleic Acid Analogs
US7666854B2 (en)2006-05-112010-02-23Isis Pharmaceuticals, Inc.Bis-modified bicyclic nucleic acid analogs
ES2388590T3 (en)2007-05-302012-10-16Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids with N-substituted aminomethylene bridge.
WO2008154401A2 (en)2007-06-082008-12-18Isis Pharmaceuticals, Inc.Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en)2007-07-052015-06-24Isis Pharmaceuticals, Inc.6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en)2007-11-212013-10-01Isis Pharmaceuticals, IncCarbocyclic alpha-L-bicyclic nucleic acid analogs
US9029524B2 (en)*2007-12-102015-05-12California Institute Of TechnologySignal activated RNA interference
WO2010036698A1 (en)2008-09-242010-04-01Isis Pharmaceuticals, Inc.Substituted alpha-l-bicyclic nucleosides
US20100249214A1 (en)2009-02-112010-09-30Dicerna PharmaceuticalsMultiplex dicer substrate rna interference molecules having joining sequences
KR20110110776A (en)2008-12-182011-10-07다이서나 파마수이티컬, 인크. Extended Dicer Substrate Formulations and Methods for Specific Inhibition of Gene Expression
WO2011017521A2 (en)2009-08-062011-02-10Isis Pharmaceuticals, Inc.Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en)2010-06-082014-09-30Isis Pharmaceuticals, Inc.Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2807307C (en)2010-08-172021-02-09Merck Sharp & Dohme Corp.Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
CA2853613C (en)2010-10-282020-03-24Benitec Biopharma LimitedHbv treatment
SI3505528T1 (en)2011-04-212021-04-30Glaxo Group LimitedModulation of hepatitis b virus (hbv) expression
TWI695066B (en)2011-06-302020-06-01美商艾羅海德製藥公司Compositions and methods for inhibiting gene expression of hepatitis b virus
US20150051389A1 (en)2011-08-112015-02-19Isis Pharmaceuticals, Inc.Selective antisense compounds and uses thereof
EP3640332A1 (en)2011-08-292020-04-22Ionis Pharmaceuticals, Inc.Oligomer-conjugate complexes and their use
EP2850092B1 (en)2012-04-092017-03-01Ionis Pharmaceuticals, Inc.Tricyclic nucleic acid analogs
WO2013159109A1 (en)2012-04-202013-10-24Isis Pharmaceuticals, Inc.Modulation of hepatitis b virus (hbv) expression
JP2016503300A (en)2012-11-152016-02-04ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Anti-ApoB antisense complex compound
BR112015027321A8 (en)2013-05-012018-01-02Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
AU2014300981B2 (en)2013-06-272017-08-10Roche Innovation Center Copenhagen A/SAntisense oligomers and conjugates targeting PCSK9
US9856472B2 (en)*2013-07-012018-01-02California Institute Of TechnologySmall conditional RNAs
EP3099797B1 (en)2014-01-302019-08-21F. Hoffmann-La Roche AGPoly oligomer compound with biocleavable conjugates
GB201408623D0 (en)2014-05-152014-07-02Santaris Pharma AsOligomers and oligomer conjugates
US20170327524A1 (en)2014-10-102017-11-16Hoffmann-La Roche, Inc.Galnac phosphoramidites, nucleic acid conjugates thereof and their use
US20170016000A1 (en)2015-07-172017-01-19Arcturus Therapeutics, Inc.Compositions and agents against hepatitis b virus and uses thereof
EP3332007A4 (en)2015-08-072019-07-17Arrowhead Pharmaceuticals, Inc. RNA INTERFERENCE THERAPY FOR HEPATITIS B VIRUS INFECTION
MA45496A (en)2016-06-172019-04-24Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
JP7288852B2 (en)2016-11-232023-06-08アルニラム・ファーマシューティカルズ・インコーポレーテッド Modified RNA agents with reduced off-target effects

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040162249A1 (en)*2002-08-292004-08-19Chun LiangTreatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotides inhibition of human replication-initiation proteins
WO2009058014A2 (en)*2007-11-022009-05-07Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En PatientenzorgPolypeptides involved in neuronal regeneration-associated gene expression
WO2013173635A1 (en)*2012-05-162013-11-21Rana Therapeutics, Inc.Compositions and methods for modulating gene expression
WO2014187856A1 (en)*2013-05-212014-11-27Deutsches KrebsforschungszentrumNucleoli disorganisation by knocking down specific alu-repeat containing rna sequences
WO2014205105A1 (en)*2013-06-192014-12-24The Regents Of The University Of CaliforniaBiomarkers of response to inhibition of poly-adp ribose polymerase (parp) in cancer
WO2016011080A2 (en)*2014-07-142016-01-21The Regents Of The University Of CaliforniaCrispr/cas transcriptional modulation
WO2016073990A2 (en)*2014-11-072016-05-12Editas Medicine, Inc.Methods for improving crispr/cas-mediated genome-editing

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AISLING FRIZZELL ET AL: "RTEL1 Inhibits Trinucleotide Repeat Expansions and Fragility", CELL REPORTS, vol. 6, no. 5, 20 February 2014 (2014-02-20), US, pages 827 - 835, XP055624538, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2014.01.034*
BARBER LOUISE J. ET AL: "RTEL1 Maintains Genomic Stability by Suppressing Homologous Recombination", CELL, vol. 135, no. 2, 16 October 2008 (2008-10-16), Amsterdam NL, pages 261 - 271, XP093246216, ISSN: 0092-8674, Retrieved from the Internet <URL:https://www.cell.com/cell/pdf/S0092-8674(08)01061-1.pdf> DOI: 10.1016/j.cell.2008.08.016*
BARBER LOUISE J. ET AL: "Supplemental Data: RTEL1 Maintains Genomic Stability by Suppressing Homologous Recombination", CELL, 16 October 2008 (2008-10-16), XP093272915, Retrieved from the Internet <URL:https://www.cell.com/cms/10.1016/j.cell.2008.08.016/attachment/22d24712-bda9-4647-a60e-40f431c76b22/mmc1.pdf> DOI: 10.1016/j.cell.2008.08.016*
DARIA V. BABUSHOK ET AL: "Disrupted lymphocyte homeostasis in hepatitis-associated acquired aplastic anemia is associated with short telomeres : Short telomeres in hepatitis-associated aplastic anemia", AMERICAN JOURNAL OF HEMATOLOGY, vol. 91, no. 2, 30 November 2015 (2015-11-30), US, pages 243 - 247, XP055623867, ISSN: 0361-8609, DOI: 10.1002/ajh.24256*
DODSON L ET AL: "Chapter 6: Dyskeratosis congenita and the telomere biology disorders", 7 June 2018 (2018-06-07), pages 111 - 135, XP009516184, ISSN: 1613-5318, ISBN: 978-3-319-61420-5, Retrieved from the Internet <URL:http://link.springer.com/10.1007/978-3-319-61421-2_6> [retrieved on 20180607]*
HARLEEN KAUR ET AL: "Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)", CHEMICAL REVIEWS, vol. 107, no. 11, 18 October 2007 (2007-10-18), US, pages 4672 - 4697, XP055623618, ISSN: 0009-2665, DOI: 10.1021/cr050266u*
MICHAEL SCHERTZER ET AL: "Human regulator of telomere elongation helicase 1 (RTEL1) is required for the nuclear and cytoplasmic trafficking of pre-U2 RNA", NUCLEIC ACIDS RESEARCH, vol. 43, no. 3, 27 January 2015 (2015-01-27), pages 1834 - 1847, XP055623869, ISSN: 0305-1048, DOI: 10.1093/nar/gku1402*
PETER H. HAGEDORN ET AL: "Locked nucleic acid: modality, diversity, and drug discovery", DRUG DISCOVERY TODAY, vol. 23, no. 1, 6 October 2017 (2017-10-06), AMSTERDAM, NL, pages 101 - 114, XP055461215, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2017.09.018*
ROSA M PORRECA ET AL: "Human RTEL1 stabilizes long G-overhangs allowing telomerase-dependent over-extension", NUCLEIC ACIDS RESEARCH, vol. 46, no. 9, 7 March 2018 (2018-03-07), pages 4533 - 4545, XP055624335, ISSN: 0305-1048, DOI: 10.1093/nar/gky173*

Also Published As

Publication numberPublication date
JP2025039668A (en)2025-03-21
MX2021000404A (en)2021-03-25
BR112021000538A2 (en)2021-04-06
JP7616987B2 (en)2025-01-17
TWI791868B (en)2023-02-11
CN112534055A (en)2021-03-19
EP3821013A1 (en)2021-05-19
EP3821013C0 (en)2024-11-27
EP3821013B1 (en)2024-11-27
CL2021000018A1 (en)2021-07-09
KR20210033004A (en)2021-03-25
JP2021524277A (en)2021-09-13
EP4512407A2 (en)2025-02-26
AU2019300324A1 (en)2021-01-21
CR20210015A (en)2021-03-22
WO2020011902A1 (en)2020-01-16
SG11202100348SA (en)2021-02-25
CA3106288A1 (en)2020-01-16
TW202020152A (en)2020-06-01
US20210147850A1 (en)2021-05-20
PE20211306A1 (en)2021-07-20
IL279929A (en)2021-03-01

Similar Documents

PublicationPublication DateTitle
MX367543B (en)Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection.
MX2020010383A (en)Use of fubp1 inhibitors for treating hepatitis b virus infection.
EP4512407A3 (en)Oligonucleotides for modulating rtel1 expression
PH12020550436A1 (en)NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
WO2008079460A3 (en)Tyrosine kinase inhibitors for prevention or treatment of infection
NZ759766A (en)Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
WO2008049856A3 (en)Methods of treating pain using cdk inhibitors
WO2007115289A8 (en)Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
SG166778A1 (en)Influenza targets
WO2012072713A3 (en)Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
IL197080A0 (en)Pyrimidone compounds as gsk-3 inhibitors
ATE376828T1 (en) USE OF ROTIGOTINE FOR THE TREATMENT AND PREVENTION OF PARKINSON PLUS SYNDROME
CL2007002346A1 (en) NON-NUCLEOSIDIC COMPOUNDS DERIVED FROM FENOXI-FENIL SUBSTITUTED, INHIBITORS OF THE HIV REVERSE TRANSCRIPT; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT PREVENT AN HIV INFECTION OR TO TREAT AIDS OR CRS.
PH12013502370A1 (en)Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
AU2018246796A1 (en)S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
HK1245678A1 (en)Compositions and methods of using tyrosine kinase inhibitors
WO2016109217A3 (en)Btk inhibitors
WO2007044325A3 (en)Apoe4 domain interaction inhibitors and methods of use thereof
MX2009000359A (en)Methods for treating and limiting fibrotic disorders and keloids.
AU2019282132A8 (en)Compositions and methods for treating pancreatitis
EP4005569A3 (en)Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2022038211A3 (en)Use of a1cf inhibitors for treating hepatitis b virus infection
ATE547105T1 (en) GLUCOSAMINE AND DERIVATIVES THEREOF AS TRANSGLUTAMINASE INHIBITORS FOR USE IN THE TREATMENT OF NERVOUS SYSTEM DYSFUNCTION
WO2019115493A3 (en)C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
MX2020010231A (en)A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor.

Legal Events

DateCodeTitleDescription
PUAIPublic reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text:ORIGINAL CODE: 0009012

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: THE APPLICATION HAS BEEN PUBLISHED

ACDivisional application: reference to earlier application

Ref document number:3821013

Country of ref document:EP

Kind code of ref document:P

AKDesignated contracting states

Kind code of ref document:A2

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REGReference to a national code

Ref country code:DE

Ref legal event code:R079

Free format text:PREVIOUS MAIN CLASS: A61K0031712500

Ipc:C12N0015113000

RIC1Information provided on ipc code assigned before grant

Ipc:A61K 31/7125 20060101ALI20250602BHEP

Ipc:A61K 31/712 20060101ALI20250602BHEP

Ipc:C12N 15/113 20100101AFI20250602BHEP

PUALSearch report despatched

Free format text:ORIGINAL CODE: 0009013

AKDesignated contracting states

Kind code of ref document:A3

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1Information provided on ipc code assigned before grant

Ipc:C12N 15/113 20100101AFI20250821BHEP

Ipc:A61K 31/712 20060101ALI20250821BHEP

Ipc:A61K 31/7125 20060101ALI20250821BHEP
[8]ページ先頭
©2009-2025 Movatter.jp